Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Feb 19, 2016
Insider Transaction Report
Form 4
Roberts Margo R
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2016-02-17$0.70/sh+9,632$6,742→ 18,730 total - Sale
Common Stock
2016-02-17$45.05/sh−9,532$429,417→ 9,198 total - Sale
Common Stock
2016-02-17$46.01/sh−100$4,601→ 9,098 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-02-17−9,632→ 62,743 totalExercise: $0.70Exp: 2023-10-07→ Common Stock (9,632 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.